Analytical sensitivity and diagnostic performance of serum protein electrophoresis on the HYDRAGEL 30 PROTEIN(E) β1-β2 Sebia Hydrasys system

Tsui, Albert K.Y.; Thomas, Dylan; Hunt, Alison; Estey, Mathew P.; Christensen, Cathy-Lou; Higgins, Trefor; Sandhu, Irwindeep; Rodríguez-Capote, Karina

doi:10.1016/j.clinbiochem.2017.09.007

Cited by 7 publications

(4 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…8,[14][15][16][17][18] The addition of IF increased the ability to detect M-proteins accurately, and recent recommendations in human medicine suggest that it might be inappropriate to diagnose a monoclonal gammopathy without IF and confirm that the electrophoretic abnormality is immunoglobulin. 19,20 TA B L E 4 Comparison of the interpretations for M-protein detection in 100 cases by two reviewers using agarose gel electrophoresis (AGE), capillary zone electrophoresis (CZE), and routine immunofixation (IF), or combinations of these tests. Reviewers could select if the provided data indicated an M-protein was present, absent, or ambiguous and required additional data.…”

Section: Discussionmentioning

confidence: 99%

Diagnostic performance of routine electrophoresis and immunofixation for the detection of immunoglobulin paraproteins (M‐Proteins) in dogs with multiple myeloma and related disorders: Part 1 – Current performance

Moore

Harris

Jeffries

et al. 2021

Veterinary Clinical Pathol

View full text Add to dashboard Cite

Background: Routine electrophoresis [agarose gel electrophoresis (AGE) and capillary zone electrophoresis (CZE)] and species-specific immunofixation (IF) can be used alone or in combination to detect immunoglobulin paraprotein (M-protein) and diagnose secretory myeloma-related disorders (sMRD). Objective: We aimed to evaluate the performance of AGE, CZE, CZE plus IF (CZE-IF), and AGE plus IF (AGE-IF) for detecting canine serum M-proteins. Methods: One hundred canine cases that had AGE, CZE, and routine IF performed on serum, and where B-cell lineage neoplasia (such as B-cell lymphoma and plasma cell tumors) had been diagnosed or excluded, were evaluated. Routine IF protocols targeted IgG-FC, IgA, and IgM heavy chains and light chains. IgG4 IF and free light chain IF were also performed. B-cell lineage neoplasms with an M-protein detected, using any available method, were classified as sMRD. Datasets from AGE, CZE, IF, CZE-IF, and AGE-IF (electrophoretograms, gel images, and fraction concentrations)were composed and reviewed. The sensitivity, specificity, and Youden's index for Mprotein detection were determined for each dataset. Results:The combination of AGE-IF or CZE-IF was more sensitive (82.9%) than CZE alone (72.0%) or AGE alone (64.6%) and more specific (66.1%, 48.3%, 51.7%, respectively). Immunofixation could be used alone to detect M-proteins (sensitivity 82.9%, specificity 61.9%), but there were technical challenges that complicated the performance and evaluation of the test. Myeloma with free light chains only was found in 5/41 cases of sMRD.Conclusions: Adding routine IF to routine electrophoresis increases the ability to accurately identify M-proteins; however, there is still room for further diagnostic performance improvements.

show abstract

Section: Discussionmentioning

confidence: 99%

Diagnostic performance of routine electrophoresis and immunofixation for the detection of immunoglobulin paraproteins (M‐Proteins) in dogs with multiple myeloma and related disorders: Part 1 – Current performance

Moore

Harris

Jeffries

et al. 2021

Veterinary Clinical Pathol

View full text Add to dashboard Cite

show abstract

“…The observed SIFE test sensitivity above the reported 200 mg/L value can be a result of myeloma sera dilutions made in a normal human serum pool that has higher normal immunoglobulin concentrations than multiple myeloma sera. Disparities in SIFE sensitivity based on the heterogeneity of M-proteins and the presence of a high normal immunoglobulin background have been reported in previously published studies. − The difference in MS signal intensities for a variety of monoclonal antibodies and M-proteins is discussed in “Supplemental Results and Discussion,” and the results are shown in Figures S5 and S6.…”

Section: Resultsmentioning

confidence: 62%

High-Throughput Therapeutic Antibody Interference-Free High-Resolution Mass Spectrometry Assay for Monitoring M-Proteins in Multiple Myeloma

et al. 2020

View full text Add to dashboard Cite

Measurement of monoclonal antibodies (M-proteins) plays an important role in the diagnosis and treatment monitoring of multiple myeloma. Currently available M-protein assays have several limitations, particularly because of their lack of sensitivity and propensity to therapeutic antibody (t-mAb) interference. A previously described mass spectrometry method termed monoclonal immunoglobulin rapid accurate mass measurement (miRAMM) is more sensitive than current clinical tests and can provide a solution for resolving t-mAb interferences. However, the original miRAMM workflow is too complex for the throughput needed to analyze a large number of samples. Here, we describe a high-throughput liquid chromatography−high-resolution mass spectrometry (HT-LC-HRMS) approach that employs a fully automated immunocapture step, significantly improved immunoglobulin recovery, simplified chromatography, and high throughput (HT) data processing. In this HT-LC-HRMS approach, raw spectra of the peaks eluting from the LC column during the predefined time period are automatically deconvoluted without the need to identify and monitor the retention time of each patient-specific M-protein. The deconvoluted peak heights of M-protein and therapeutic antibody light chain are conveniently used for quantitation. With the total LC-HRMS measurement time being only 11.0 min, this method was able to differentiate between the M-protein and elotuzumab mass signatures in 91 out of 92 (98.9%) multiple myeloma serum samples tested. The single interference case was resolved using the mass signature of a heavy chain. In addition to resolving t-mAb interference, the developed assay has a 25-fold improvement in sensitivity over immunofixation electrophoresis and can potentially provide an objective tracking of M-proteins in patients with complete response.

show abstract

“…The Hydroscan 2 system (Sebia, Lisses, France) was employed to quantify the different lipoprotein subfractions. On each gel, a normal control was used to check the electrophoresis process and the staining procedures [ 26 ].…”

Section: Methodsmentioning

confidence: 99%

Effect of the Fat Eaten at Breakfast on Lipid Metabolism: A Crossover Trial in Women with Cardiovascular Risk

et al. 2020

View full text Add to dashboard Cite

Recent studies point out that not only the daily intake of energy and nutrients but the time of day when they are ingested notably regulates lipid metabolism and cardiovascular risk (CVR). Therefore, the aim of the study was to assess if the type of fat ingested at breakfast can modify lipid metabolism in women with CVR. A randomized, crossover clinical trial was performed. Sixty volunteers were randomly assigned to a (A) polyunsaturated fatty acid (PUFA)-rich breakfast, (B) saturated fatty acid (SFA)-rich breakfast, or (C) monounsaturated fatty acid (MUFA)-rich breakfast. Plasma lipoprotein and apolipoprotein subfractions were determined. Our data showed that the PUFA-rich breakfast decreased lipoprotein (a) (Lp(a)), very low-density lipoproteins (VLDL), and intermediate-density lipoproteins (IDL), and increased high-density lipoproteins (HDL). A similar trend was observed for the MUFA-rich breakfast, whereas the SFA-rich breakfast, although it decreased VLDL, also increased IDL and reduced HDL. The PUFA-rich breakfast also decreased β-lipoproteins and apolipoprotein-B. In summary, varying the type of fat eaten at breakfast is enough to significantly modify the lipid metabolism of women with CVR, which can be of great relevance to establish new therapeutic strategies for the treatment of these subjects.

show abstract

Analytical sensitivity and diagnostic performance of serum protein electrophoresis on the HYDRAGEL 30 PROTEIN(E) β1-β2 Sebia Hydrasys system

Cited by 7 publications

References 8 publications

Diagnostic performance of routine electrophoresis and immunofixation for the detection of immunoglobulin paraproteins (M‐Proteins) in dogs with multiple myeloma and related disorders: Part 1 – Current performance

Diagnostic performance of routine electrophoresis and immunofixation for the detection of immunoglobulin paraproteins (M‐Proteins) in dogs with multiple myeloma and related disorders: Part 1 – Current performance

High-Throughput Therapeutic Antibody Interference-Free High-Resolution Mass Spectrometry Assay for Monitoring M-Proteins in Multiple Myeloma

Effect of the Fat Eaten at Breakfast on Lipid Metabolism: A Crossover Trial in Women with Cardiovascular Risk

Contact Info

Product

Resources

About